Abstract

Objective: To analyze the influence of tranexamic acid in postoperative bleeding of cardiac surgery with cardiopulmonary bypass.

Method: 51 patients who underwent heart surgery with cardiopulmonary bypass were randomly divided in 2 groups: Group I – control, with 12 coronary artery disease patients and 14 valve disease patients. Group II – Tranexamic acid, with 14 coronary artery disease patients and 11 valve disease patients. The Group I after venous access, received 250 ml of 0.9% normal saline solution as a placebo, Group II received 100 milligram per kilogram of body weight of tranexamic acid diluted in 250 ml of 0.9% normal saline solution. Blood samples were taken and examined at entry to Intensive care unit and after 12, 24 and 36 hours in the postoperative period. The groups were compared concerning factors which might influence the postoperative bleeding and transfusion required: age, gender, creatinine, duration of Cardiopulmonary bypass, hematocrit, platelets and fibrinogen variations, number of saphenous vein grafts performed, mammary artery used and valve replacement or repair. The postoperative bleeding was evaluated from the 1st to 4th hours and the total. Data were analyzed by appropriate statistic methods (Student T-test, X² test and Fischer’s test); a p-value of less than 0.05 was the accepted level of significance.

Results: Concerning the postoperative bleeding and transfusion required, there was a statistically significant reduction in its average in valve disease patients in Group II. In coronary disease patients there was only a slight tendency. There was no significant statistical difference as far as the thromboembolic or renal complications were concerned.

Conclusion: In valve disease patients, there was a reduction in bleeding and the need of transfusions of red blood cells, both of which had statistical differences. In coronary disease patients there was only a reduced tendency. The use of tranexamic acid was not related to further thromboembolic complications or renal insufficiency in the assessed groups.

Descriptors: Tranexamic acid, therapeutic use. Cardiac surgical procedures. Fibrinogen
INTRODUCTION

Despite all the efforts of researchers dedicated to the task of minimizing the deleterious effects of artificial circulation, this continues to determine numerous alterations in the organism, among which are related to hemostatia, and can cause excessive bleeding in the post-operative period [1-8].

The frequency of excessive bleeding varies between available publications depending on the definition used. An incidence of 13 to 16% was observed when abnormal bleeding was considered to be a necessity of transfusions greater than 10 units of blood in the peri-operative period. However, 5 to 7% of the patients presented with excessive bleeding when this was defined as drainage of 2000 ml or more in the first 24 hours, as reported by DESPOTIS et al. [9]. KARSI et al. [10] on the other hand, reported an incidence of 18% of all patients submitted to surgery using cardiopulmonary bypasses (CPB), which bore a greater necessity of blood and its derivatives, increasing the risk of infection and transfusional reactions.

The use of drugs to reduce bleeding in the post-operative period of CPB assisted heart surgery has been studied since the report by MAMMEM et al. [11] with aprotinin in 1968.

Since the start of 1980, there has been growing interest in methods to minimize the exposure to blood and its derivatives in the peri-operative period, as it was discovered that HIV could be transmitted by transfusions [1,5,12].

Tranexamic acid is one synthetic antifibrinolytic agent – it is isomer trans 4 aminoethylcyclohexanocarboxylic, abbreviated to AMCHA -, has a plasmatic half-life of 80 minutes, only 3% binds to proteins and 95% is excreted by the kidneys. The antifibrinolytic effect of tranexamic acid results from the formation of a reversible complex of the drug with the plasminogen and the plasmin that inhibit fibrinolysis, preventing the lyse of fibrin coagulation. It also acts, creating a partial block of platelet aggregation during CPB induced by the plasmin [4,13,14].

OBJECTIVE

To evaluate the influence of tranexamic acid on post-operative bleeding of patients submitted to CPB assisted heart surgery.

METHOD

The study was performed in the Cardiac Surgery Department of Santa Casa de Montes Claros, in the period from February to October 2001, on 51 patients submitted to primary surgery of coronary artery bypass grafting or valve surgery.

The exclusion criteria were associated surgeries, patients using platelet anti-aggregation (within the previous 7 days), reoperations and history of blood disease. Prophylactic antibiotic therapy was performed in all patients according to the norms of the Infection Control Commission of the Hospital, with the administration of 2.0 g of Cephalotin, after

RESULT

An incidence of 13 to 16% was observed when abnormal bleeding was considered to be a necessity of transfusions greater than 10 units of blood in the peri-operative period. However, 5 to 7% of the patients presented with excessive bleeding when this was defined as drainage of 2000 ml or more in the first 24 hours, as reported by DESPOTIS et al. [9]. KARSI et al. [10] on the other hand, reported an incidence of 18% of all patients submitted to surgery using cardiopulmonary bypasses (CPB), which bore a greater necessity of blood and its derivatives, increasing the risk of infection and transfusional reactions.

The use of drugs to reduce bleeding in the post-operative period of CPB assisted heart surgery has been studied since the report by MAMMEM et al. [11] with aprotinin in 1968.

Since the start of 1980, there has been growing interest in methods to minimize the exposure to blood and its derivatives in the peri-operative period, as it was discovered that HIV could be transmitted by transfusions [1,5,12].

Tranexamic acid is one synthetic antifibrinolytic agent – it is isomer trans 4 aminoethylcyclohexanocarboxylic, abbreviated to AMCHA -, has a plasmatic half-life of 80 minutes, only 3% binds to proteins and 95% is excreted by the kidneys. The antifibrinolytic effect of tranexamic acid results from the formation of a reversible complex of the drug with the plasminogen and the plasmin that inhibit fibrinolysis, preventing the lyse of fibrin coagulation. It also acts, creating a partial block of platelet aggregation during CPB induced by the plasmin [4,13,14].

OBJECTIVE

To evaluate the influence of tranexamic acid on post-operative bleeding of patients submitted to CPB assisted heart surgery.

METHOD

The study was performed in the Cardiac Surgery Department of Santa Casa de Montes Claros, in the period from February to October 2001, on 51 patients submitted to primary surgery of coronary artery bypass grafting or valve surgery.

The exclusion criteria were associated surgeries, patients using platelet anti-aggregation (within the previous 7 days), reoperations and history of blood disease. Prophylactic antibiotic therapy was performed in all patients according to the norms of the Infection Control Commission of the Hospital, with the administration of 2.0 g of Cephalotin, after
venous access and at each 6 hours thereafter for 36 hours.

**Study Protocol**

A total of 51 patients admitted for coronary artery bypass grafting or valve surgery assisted by CPB were studied.

The study protocol was based on two randomized groups to complete this prospective research, where group I was a control group and Group II the tranexamic acid group.

Renal lesions were considered to be present when the value of creatinine was 50% higher than in the pre-operative period.

The Ethics Commission of the post graduation in the Cardiovascular Medical foundation of São Francisco de Assis, assessed this work.

**Group I – Control**

Sixteen male and 10 female patients with ages ranging from 15 to 70 years (mean 48.2 ± 16.8) constituted the control group. The underlying disease in 12 patients was coronary arteriosclerosis and 14 patients were suffering from valve disease, one, a double mitral-aortic injury, 4 with insufficiency, 3 with mitral stenosis, 1 aortic stenosis and 5 aortic insufficiency.

**Group II – Tranexamic acid**

Fourteen male and eleven female patients with ages varying from 20 to 74 years (mean 52.6 ± 17.4) made up this group. The underlying disease was coronary arteriosclerosis in 14 patients, and 11 patients had valve disease, 1 with a double aortic lesion and mitral insufficiency, 3 with aortic insufficiency, 3 with insufficiency and 4 with mitral stenosis.

Included in the protocol was the infusion of 100 mg/kg of body weight of tranexamic acid diluted in 250 ml of 0.9% normal saline solution, immediately after venous access was achieved, for group II and in group I an infusion of 0.9% normal saline solution.

The criteria of transfusion for the patients were: hemoglobin at 9.0 g/dL as a reference for RBC concentrate transfusion, alterations of 50% in the prothrombin activity or as an expander in the patients with signs of hypovolemia for plasma transfusion, platelets < 90,000 U/mm³ for platelet transfusion and increased bleeding with a drop in the initial value of fibrinogen for the transfusion of cryoprecipitate.

**METHOD**

In all patients, the following pre-operative laboratory examinations were performed: hemogram, platelet count, fibrinogen level, prothrombin activity, INR, TTPa, urea, creatinine, blood gas levels and sodium, potassium and magnesium levels.

Also coronary cineangiography was performed in coronary disease patients and in the over 35-year-old male and over 40-year-old female valve disease patients. An echocardiogram was made in all patients.

**Cardiopulmonary bypass technique**

A pump with rollers was used on the arterial line and membrane oxygenators with a filter on the arterial line (DMG – Equipamentos Médicos LTDA, Duque de Caxias – RJ). Myocardial protection was by anterograde hypothermic Saint Thomas-type cardioplegic solution every 20 minutes. All the patients were operated at normothermia. Heparinization was made with the intention of maintaining the activated coagulation time (ACT) greater than or equal to 480 seconds and reversal of heparin was achieved with protamine at a dose of 1:1.3 with an initial infusion of 1:1 and subsequently an infusion of 1:0.3 over four hours.

**Statistical Study**

Continuous data was assessed using the student T-test and, depending on the case, the correction of Welch was utilized. Categorical data were analyzed with X² and, depending on the observed values, Yate's correction was used. In some situations, the Fisher’s exact test was employed. The collected data represented non-paired samples, thus, all the tests took into consideration this fact. In all tests a p-value of less than 0.05 was considered significant.

**RESULTS**

There were no cases of myocardial infarction, pulmonary thromboembolism nor strokes with definitive sequels in the studied casuistic.

In Group I there was one case of kidney failure in a patient with coronary arteriosclerosis (8.33%), case 7 and one case in the valve disease patients, (7.14%) case 13. In Group II there was a case of kidney failure in the coronary arteriosclerotic patients (7.14%) and one case in the valve disease patients (9.09%); cases 2 and 5 respectively. All these cases evolved well without the necessity of hemodialysis.

There was one reoperation case in the valve disease patients of Group I due to excessive bleeding. During the re-exploratory surgery there was no evidence of active bleeding, so only the blood clots present were removed. There were no reoperations in Group II.
There was one death in Group II in the coronary arteriosclerotic patients (7.14%), case 2: the patient went for an urgent surgery with cardiogenic shock. In Group I there were two deaths in the coronary arteriosclerotic patients (16.6%), case 1 due to ARAS and case 4 because of low cardiac output. Statistical analysis did not reveal significant differences.

In relation to the variations in the mean ages, genders, body surface, ACT, platelet count, hematocrit count, creatinine levels and CPB times of the patients in the two groups, there was no significant difference. But the variations of the means of fibrinogen presented a statistical difference in the patients with coronary arteriosclerosis in the time intervals of 12 and 24 hours (p-value = 0.008 and 0.04 respectively) with a lower consumption in Group II. In the valve disease patients there was a statistical difference in variations of the PaTT means at 12 and 24 hours (p-value = 0.04 and 0.01 respectively) and in the variations of both the pre-operative and 24-hours averages of international normalized index (INR) (p = 0.02 and 0.01 respectively) with higher values in Group I – Tables 1 and 2.

In relation to bleeding in the post-operative period measurements in ml/hour were made using thoracic drains in the 1st, 2nd, 3rd and 4th hours and total volume removed. The means and the standard deviation of the bleeding for the respective times and the total bleeding in Group I (ml/hour) in the coronary arteriosclerotic patients were: 52.1 (± 69.4); 87.9 (± 63.3); 36.7 (± 36.5); 51.7 (± 37.6); 541.3 (± 275.5). In the valve disease patients they were from 103.6 (± 81.9); 88.9 (± 47.6); 60.4 (± 53.8); 70.0 (± 58.8); 775.4 (± 740.0). In Group II, the respective means were from 84.3 (±109.7); 47.1 (± 40.0); 37.5 (± 26.3); 37.5 (± 30.5); 464.3 (± 274.6) and from 54.5 (± 40.0); 48.6 (± 37.0); 30.0 (± 20.4); 30.0 (± 18.9); 407.3 (± 256.1). Using the Mann-Whitman test, a significant difference was observed in the 2nd hour (p = 0.02), in the 4th hour (p=0.01) and in the total blood volume (p = 0.04) in the valve disease patients. The mean units of transfused blood per coronary arteriosclerotic patients of Group I were 275.0 ml of RBC concentrates, 33.3 ml of plasma, infusion of platelets was not necessary. In the coronary arteriosclerotic patients of Group II the mean units of transfused blood were 276 ml of RBC concentrate, 71.4 ml of plasma, infusion of platelets was not necessary. In the coronary arteriosclerotic patients of Group I the mean units of transfused blood per valve disease patients in Group I were 514.3 ml to RBC concentrates, 171.4 ml of plasma and 4.28 U of platelets. The mean units of transfused blood per patient with valve disease of Group II were 109.1 ml of RBC concentrates, 18.2 ml of plasma and 0.9 U of platelets. Statistical analysis of these measurements, using the non-parametric test of Mann-Whitney, revealed statistical significance for the volume of RBC concentrates (p = 0.04) in valve disease patients of Group II – Table 3 and 4.

**COMMENTS**

Heart surgery is traditionally associated with a high risk of transfusions of blood and its derivatives [1-3,7,14-17]. According to some authors, the main mechanisms that explain bleeding after CPB, are fibrinolysis, platelet alterations and intravascular coagulation with consumption of the coagulation factors [1,3,6,13,18,19]. In this investigation a 3.0 mg/kg body weight dose of heparin was utilized as the first dose with complementary

---

**Table 1. Comparison between the Demographic, clinical and biochemical parameters of the patients with coronary arteriosclerosis of Groups I and II.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I (n=12)</th>
<th>Group II (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59.00</td>
<td>63.71</td>
</tr>
<tr>
<td>ACT (seconds) Initial</td>
<td>123.8</td>
<td>126.4</td>
</tr>
<tr>
<td>ACT (seconds) Post protamine</td>
<td>160.4</td>
<td>149.9</td>
</tr>
<tr>
<td>PaTT (seconds) Pre-operative</td>
<td>37.9</td>
<td>45.5</td>
</tr>
<tr>
<td>PaTT (seconds) T-12</td>
<td>45.3</td>
<td>42.4</td>
</tr>
<tr>
<td>PaTT (seconds) T-24</td>
<td>41.3</td>
<td>48.3</td>
</tr>
<tr>
<td>PaTT (seconds) T-36</td>
<td>41.9</td>
<td>46.2</td>
</tr>
<tr>
<td>PaTT (seconds) Pre-operative</td>
<td>44.8</td>
<td>43.9</td>
</tr>
<tr>
<td>INR (seconds) Pre-operative</td>
<td>1.10</td>
<td>1.12</td>
</tr>
<tr>
<td>INR (seconds) T-12</td>
<td>1.28</td>
<td>1.30</td>
</tr>
<tr>
<td>INR (seconds) T-24</td>
<td>1.31</td>
<td>1.19</td>
</tr>
<tr>
<td>INR (seconds) T-36</td>
<td>1.23</td>
<td>1.22</td>
</tr>
<tr>
<td>INR (seconds) Pre-operative</td>
<td>1.27</td>
<td>1.31</td>
</tr>
<tr>
<td>INR (seconds) T-12</td>
<td>1.28</td>
<td>1.90</td>
</tr>
<tr>
<td>INR (seconds) T-24</td>
<td>1.88</td>
<td>1.91</td>
</tr>
<tr>
<td>INR (seconds) T-36</td>
<td>1.65</td>
<td>1.85</td>
</tr>
<tr>
<td>Platelets (x 1000) Pre-operative</td>
<td>212.3</td>
<td>226.6</td>
</tr>
<tr>
<td>Platelets (x 1000) ICU Entry</td>
<td>189.9</td>
<td>201.1</td>
</tr>
<tr>
<td>Platelets (x 1000) T-12</td>
<td>182.8</td>
<td>190.3</td>
</tr>
<tr>
<td>Platelets (x 1000) T-24</td>
<td>168.8</td>
<td>191.1</td>
</tr>
<tr>
<td>Platelets (x 1000) T-36</td>
<td>163.5</td>
<td>185.2</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL) Pre-operative</td>
<td>261.1</td>
<td>269.1</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL) ICU Entry</td>
<td>230.3</td>
<td>238.9</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL) T-12</td>
<td>217.1</td>
<td>260.9*</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL) T-24</td>
<td>259.8</td>
<td>272.9*</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL) T-36</td>
<td>261.7</td>
<td>263.9</td>
</tr>
<tr>
<td>Hematocrit (%) Pre-operative</td>
<td>43.9</td>
<td>40.8</td>
</tr>
<tr>
<td>Hematocrit (%) ICU Entry</td>
<td>36.3</td>
<td>33.5</td>
</tr>
<tr>
<td>Hematocrit (%) T-12</td>
<td>35.3</td>
<td>32.7</td>
</tr>
<tr>
<td>Hematocrit (%) T-24</td>
<td>33.2</td>
<td>32.1</td>
</tr>
<tr>
<td>Hematocrit (%) T-36</td>
<td>30.2</td>
<td>30.7</td>
</tr>
<tr>
<td>Creatinine (mg/dL) Pre-operative</td>
<td>1.01</td>
<td>0.94</td>
</tr>
<tr>
<td>Creatinine (mg/dL) ICU Entry</td>
<td>0.86</td>
<td>0.86</td>
</tr>
<tr>
<td>Creatinine (mg/dL) T-12</td>
<td>0.99</td>
<td>1.05</td>
</tr>
<tr>
<td>Creatinine (mg/dL) T-24</td>
<td>1.10</td>
<td>1.09</td>
</tr>
<tr>
<td>Creatinine (mg/dL) T-36</td>
<td>1.03</td>
<td>0.99</td>
</tr>
</tbody>
</table>

T-12 = 12 hours, T-24 = 24 hours, T-36 = 36 hours * p < 0.005
doses at 30 minute intervals of CPB with the aim of maintaining the ACT > 480 seconds.

Several factors are implicated in the alterations in coagulation: surgical causes, heparin rebound, complementary activation, hyperfibrinolysis and platelet dysfunction. [13,20]. Previous studies demonstrated that platelet dysfunction and the excessive fibrinolysis are the most common non-surgical causes [2,3,21]; contact of blood with the non-endothelium surface of the CPB activates the coagulation system, fibrinolysis and platelets [7,19,20,22,23].

To neutralize the heparin rebound effect, which occurs in the first hours of the post-operative period, as a cause of increased bleeding, the total dose of protamine (1:1.3) was divided in 1:1 diluted in 100 ml of 0.9% normal saline solution infused drop-by-drop. The remaining 1:0.3 of protamine was infused diluted in 100 ml of 0.9% normal saline solution in the infusion pump in a four hour period in both groups.

The increase in the morbidity and the mortality caused by increased bleeding led to the realization of this study with tranexamic acid; chosen because of the ease of use and its low cost. Because of the liberation of plasminogen activators at the start of the incision phase of the skin, we decided to begin tranexamic acid administration soon after venous access was achieved, so its peak of action would occur during the sternotomy and during the period of CPB [3,18].

PUGH & WIELOGORSKI [19], in a prospective study,
Comparing tranexamic acid with low doses of aprotinin, concluded that tranexamic acid presented the same efficiency to aprotinin when compared with placebos in patients submitted to the first heart surgery. MAINERI et al. [7], studied 48 patients randomly divided in two groups, 1 using epsilon-aminocaproic acid and the other tranexamic acid, reported that there was no statistical difference in the two groups in relation to bleeding in the post-operative period or in the necessity of transfusion of blood or derivatives. There were no events related to hypercoagulation; fibrinolysis was effectively inhibited and there was no excessive bleeding in the two groups. They concluded that both tranexamic acid and epsilon-aminocaproic acid can be safely used to control fibrinolysis and bleeding in surgeries with CPB.

In this investigation, data referring to age, gender, body surface, number of coronary and valve disease patients, utilization or not of internal thoracic artery, the number of saphenous vein grafts performed, valve replacement or reconstruction surgeries, CPB time did not present significant variations, which demonstrated that the groups were comparable.

In this study, partial hemodilution was used in the two groups, where in Group I, a reduction in the average fibrinogen of 11.8% in the coronary arteriosclerotic patients and 20.94% in the valve disease patients was seen at entry to the ICU. In Group II the reduction was of 11.23% and 12.06% for the coronary arteriosclerotic patients and valve disease patients respectively. The variation in the platelets averages, as well as hematocrit mean variations, due to transfusions of RBC concentrates and platelets, did not experience statistically significant differences except for those of the coronary patients at entry to ICU (p = 0.03).

In relation to bleeding in the post-operative period of heart surgery using CPB, DUNN & GOA [14] concluded that tranexamic acid is useful in a reduction of from 29 to 54% when compared with a placebo. PUGH & WIELOGORSSHI [19] reported a loss of 1000 ml on average in patients submitted to the first surgery, concluding that effective methods to minimize this loss would be beneficial.

In this work the post-operative bleeding was studied. Due to the fact that hemodynamic instability is more frequent in the first hours, the investigation was concentrated in the initial four post-operative hours, from when, in general, stabilization in the drainage occurs. Only in the first and third hours the average bleeding in patients submitted to coronary artery bypass grafting of Group II was greater than the bleeding in the patients of Group I (52.1 vs. 84.3 ml and 36.7 vs. 37.5 ml for 1st and 3rd hours respectively). At the other times, they were lower both for patients submitted to coronary grafting procedures and for valve surgery. This resulted in a final drainage mean lower in Group II; with significant difference for valve disease patients with p = 0.04 (775.4 ml vs. 407.3 ml). These results support those of WONG et al. [8], who evaluated 80 patients submitted to heart surgery with high risk of bleeding in a double-blind random study using high doses of aprotinin or tranexamic acid.

In the patients who underwent coronary artery bypass grafting in particular, the tendency of reduced bleeding is in accordance with the studies by VARGAS et al. [20] and by COUTO et al. [21]. In both investigations the same quantities of tranexamic acid were used although with different surgical durations.

The mean reduction of post-operative bleeding of the patients of Group II submitted to valve surgeries reflected directly in the reduction of average RBC concentrates transfused when compared to Group I (541.3 vs. 109.1) with a statistically significant difference (p = 0.04), consistent with the results of GEROMETTA et al. [24].

An important point is about the safety of using antifibrinolytic drugs which refers to the risk of thrombosis, particularly with venous grafts. MAINERI et al. [7] reported not having any negative events related to hypercoagulability. CASATI et al. [2] reported the same incidence of perioperative infarction with the use of aprotinin and tranexamic acid (2%). WESTABY & KATSUMATA [25] reported a greater incidence of occlusion of smaller caliber venous grafts (15.4 aprotinin group vs. 10.9 control group). Incomplete coronary artery bypass grafting due to early occlusion of the grafts can lead to late myocardial infarction and recurrent angina of the patient and reduce the event-free time suggesting the necessity of precautions with the utilization of aprotinin.

In relation to the presented complications, there were no significant variations associated to cases of acute perioperative myocardial infarction, pulmonary thromboembolism or stroke with definitive sequels in the study group.

The routine use of tranexamic acid in heart surgery with CPB still requires further studies with greater numbers of patients to establish its clinical application and a better observation of the possible side effects.

**CONCLUSION**

1. The use of tranexamic acid, in patients submitted to valve surgeries, determined a reduction of bleeding and a decrease...
in the RBC concentrate transfusions. In patients submitted to coronary artery bypass grafting, there was only a reduced tendency of bleeding.

- The utilization of tranexamic acid did not increase the incidence of thromboembolic complications or kidney failure.

**BIBLIOGRAPHIC REFERENCES**


